### Supplementary Table 3. Baseline characteristics of included studies based on immunization experiments with protein vaccines against *Toxoplasma gondii* in mouse models (single antigens)

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Adjuvant or carrier</th>
<th>Ag delivery</th>
<th>Mouse strain</th>
<th>Challenge</th>
<th>Immune responses</th>
<th>Brain cyst load</th>
<th>Survival</th>
<th>Conclusions or suggestions</th>
<th>Reference</th>
</tr>
</thead>
</table>
| MIC1    | FCA and FIA s.c     | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Induced a strong IgG antibody response (p<0.05)  
  
  Induced mixed Th1/Th2 immune responses with predominance of IgG2b over IgG1 (p<0.05)  
  
  Splenocyte proliferation (p<0.05)  
  
  IFN-γ and IL-10 (p<0.05) | Reduced (52%, p<0.05) | Increased survival rate (50%, 30-day post challenge, p<0.05)  
  
  Control mice were died within 11 days. | The use of this vaccine offers a promising strategy for conferring protection against toxoplasmosis. | [21] |
| MIC4    | FCA and FIA s.c     | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Induced a strong IgG antibody response (p<0.05)  
  
  Induced mixed Th1/Th2 immune responses with predominance of IgG2b over IgG1 (p<0.05)  
  
  Splenocyte proliferation (p<0.05)  
  
  IFN-γ and IL-10 (p<0.05) | Reduced (46.9%, p<0.05) | Increased survival rate (50%, 30-day post challenge, p<0.05)  
  
  Control mice were died within 11 days. | The use of this vaccine offers a promising strategy for conferring protection against toxoplasmosis. | [21] |
| MIC6    | FCA and FIA s.c     | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Induced a strong IgG antibody response (p<0.05)  
  
  Induced mixed Th1/Th2 immune responses with predominance of IgG2b over IgG1 (none significant)  
  
  Splenocyte proliferation (p<0.05)  
  
  IFN-γ and IL-10 (p<0.05) | Reduced (27.2%, none-significant) | Increased survival rate (40%, 30-day post challenge, p<0.05)  
  
  Control mice were died within 11 days. | The use of this vaccine offers a promising strategy for conferring protection against toxoplasmosis. | [21] |

MIC, microneme proteins; FCA, Freund's complete adjuvant; IFN-γ, interferon-γ; IL, interleukin; Th1, T helper 1.

### Supplementary Table 4. Baseline characteristics of included studies based on immunization experiments with protein vaccines against *Toxoplasma gondii* in mouse models (mixed antigens)

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Adjuvant or carrier</th>
<th>Ag delivery</th>
<th>Mouse strain</th>
<th>Challenge</th>
<th>Immune responses</th>
<th>Brain cyst load</th>
<th>Survival</th>
<th>Conclusions or suggestions</th>
<th>Reference</th>
</tr>
</thead>
</table>
| MIC1+MIC4 | FCA and FIA s.c    | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Mixed IgG1/IgG2a response (p<0.05)  
  
  Induced Th1/Th2 immune responses with predominance of IgG2a over IgG1 (9,274 ± 1,608 pg/mL, p<0.05),  
  
  IFN-γ (3,274 ± 2,151 pg/mL, p<0.05),  
  
  IL-2 (50 ± 5 pg/mL, p<0.05), and IL-10 (1,608 ± 300 pg/mL, p<0.05) | Reduced (68%, p<0.05) | Increased survival rate (80%, 30-day post challenge, p<0.05)  
  
  Control mice were died within 11 days. | The data demonstrate that MIC1 and MIC4 triggered a protective response against toxoplasmosis, and that these antigens are targets for the further development of a vaccine. | [22] |
| MIC1+MIC4 | FCA and FIA s.c    | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Induced a strong IgG antibody response (p<0.05)  
  
  Induced mixed Th1/Th2 immune responses with predominance of IgG2b over IgG1 (67.8%, p<0.05)  
  
  Splenocyte proliferation (p<0.05)  
  
  IFN-γ, IL-12 p-40, and IL-10 (p<0.05) | Reduced (59%, p<0.05) | Increased survival rate (70%, 30-day post challenge, p<0.05)  
  
  Control mice were died within 11 days. | Our results demonstrate that microneme proteins are potential vaccines against *T. gondii*, since their inoculation prevents or decreases the deleterious effects of the infection. | [21] |
| MIC1+MIC4+MIC6 | FCA and FIA s.c | C57BL/6     | (H-2b)      | 40 and 80 cysts of the ME49 strain, orally | Induced a strong IgG antibody response (p<0.05) | Reduced (67.8%, p<0.05) | Increased survival rate (80%, 30-day post challenge, p<0.05) | Our results demonstrate that microneme proteins are potential vaccines against *T. gondii*, since their inoculation prevents or decreases the deleterious effects of the infection. | [21] |

MIC, microneme proteins; s.c, subcutaneous; IFN-γ, interferon-γ; IL, interleukin; Th1, T helper 1.